  
 

 

 

 

 

 

 

 

 

 

 

 

 


     . , ,  .          ,      .





 ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  

  





 


   

   

   

   

  

    

   

    

-2     2 

   

    

  - 

  

  

-      

-    

-    

   

    

  ,   

   

     

    

    

  - 

  

  

   -

-1   -1

   

    

    

   

   

   

    

    

  

  - 

   

    

   

    

    

   

    

-1     1

-      

   

     

  -

   

   

      

   

-    -

    

    

-     

   

  

   

  

    

  - 

     

    

     

     

   

    

   

    

    

    

     

   

    

    

     

    

      

      

   

-     

   

  

   

   

    

   

    

    

  

    

   

  

   

    

  - 

       

    

  

   

  

    

   

1    1 

2    2 

      

    

    

      

    

-1     1 

-2     2 

     

    

  - 

     

  - 

  - 

   

    

  

     

   

   

     

   

   

   

  , , 

-23     23

   

  

    

    

    

    

    

   

    

    

    

    

  - 

    

   

  

   

  

   

1-     

17-  17-

2-     

AACB (The Australasian Association for Clinical Biochemistry and Laboratory Medicine)       

 (American Association of Clinical Endocrinology)    

 (American College of Endocrinology)   

ADA  American Diabetes Association    

AIRE (autoimmune regulator)  

 (Associazione Medici Endocrinologi)   

 (American Thyroid Association)   

CIRCI (critical illness-related corticosteroid insufficiency)     

DXA (DEXA) (dual energy X-ray absorptiometry)   

ESA (Endocrine Society of Australia)   

ESICM (European Society of Intensive Care Medicine)    

EU-TIRADS (thyroid imaging reporting and data system)         

FDA (Food and Drug Administration)         (  )

FE (fractional excretion)  

FFH (familial hypocalciuric hypercalcemia)    

GADA    

HbA1c   

HLA    

HOMA-IR    

IAA    

ICA     

LADA (latent autoimmune diabetes in adults)    

MODY (maturity onset diabetes of the young)     

NB (nota bene)  

NICE (National Institute of Health and Care Excellence)       

P1NP (procollagen type 1 N-terminal propeptide)  N-   1 

RCPA (Royal College of Pathologists of Australasia)    

SaO


    

SCCM (Society of Critical Care Medicine)    

SD (standard deviation)  

SST (serum-separating tubes)     

VHL-      

ZnT8     -8

?-  -   




 





  1 








 



 

  1 ,  ,       (< 3040),         (  , , ) [4].

             ( ,     , -   - );           .

        ( ,  ,  , ,  ,   .) [14].


,      1 

   (       )

 

   

      / 

 

  ,  

  

   

  

   

 

      :

?  (,    , ,   ..)

?  (, )

?  (  ,    )


 

 20%  1      ()   .    ,     [5]:

   :  , , ,  ,   (    )

   :  (    )

   :  (  )

    :   

    /   (  ,     ,    )




   1 



     1     (  )            HbA1c,         1   :

       1      [5];      1            (   ),      [3];

    1        ,      ,     HbA1c [3],             [5].




   



  

    (  8    14  ),    .        ,    .        ,   ,  .  1    .  ,       (, ,  , , ,   .)       .




      ,   (,    .), ,     .


  

            (  2 ),        (  + )     [3, 6].


 



 1







           8,    14 .




             :

?     *       ;

?              ;

?          ,     ;       .

*      .






      1 


  ,      (),      [1],              :

                     [1];

            /            () [7],   /  , ,  ,    1.


  

 ,  1012   ,    ,    ,    ,    (, );   .      .             .       .            .            57 .

 :      () .


  

     ,         2  .     (   12 )   ,  ,   ,   ,             50100.            48.


 

        .   /       .



 2

    ,     [8]









 :       ( ),          [8].




    -     


   - (ICA, GADA, IA2A, IAA, ZnT8)     1          1,           .        .       ?-   ICA.




1.        1       (        1 ).

2.  LADA   2    .

3.   1      (MODY).


  

   .        34     .


 



 3






*      JDF (Juvenile Diabetes Foundation):    5; ,    1:4 4 ? 5 = 20 JDF.



 4




[9]




    

         1       1 ,          ,     1     [10].

       1 ,     10%    [11].

  ,    IAA       ,            [11].




    -   





1.    :

a) 1  2 

b) 2   LADA

c) 1     MODY

2.          .


  


  -      :   8    14  ,     

 

1.   - ().

2.    -  2    :   ,  50  (, 100 , 25  , 200   20 ).


 



 5






 6









   1 



    1    :

1)  2 ;

2)   MODY;

3)    (, LADA);

4) .




  2 


  2       (3040  );   ,  ,    ,     ()  .     (   2,      ),        .          ( -, -  ,  ),         .    :  , ,  .     [1, 2].



 7




[1]



           :  HOMA-IR ,  -   /,   -     .    (  ,     ..).


   (HOMA-IR)

 HOMA-IR           [8, 10]:



HOMA-IR =      (/) x      (/) / 22,5


  ,   HOMA-IR,   75        2,7 (  HOMA-IR < 2,7)    2060   ,              [13].   HOMA-IR    ,      [14]:

1)    (31%)        (, -);

2)           ;

3)  ,       (      ,    ).




   MODY


    1,     MODY                 .     - ,     -        .      MODY 2  3 [15].

  MODY 2:     (5,58 /)     ,  HbA1c     /  ,        (2, , ) [15].

  MODY 3:       ( 12,014,0 /)           [15].

  MODY           25    [5],     -  ,    :

    (5,58 /) [3]

        [15] (-    [5])

  ,      [5]

   HbA1c   5,67,6%,      [3]

- ,     ,      MODY,        ,        1  2  (  ,   ..),            [3, 15],  ,     1       ( 0,5 //)      [16].



 8




[17, 18]






   LADA


  LADA (   )     1         1    2 .   LADA      2 :    ,   ,     ,     LADA   .    ?-            .              (  GAD  ICA),   ,    -    ,    35    ,             6    [19, 20].



 9









 


   3       ,   20%     ,     DEND- (        ) [15].




         30 







[21]   - ,    .




 


1. ..  . .: -, 2018.

2. .. :    .  / .. , .. , .. . .: -, 2016.

3.Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes  2019 / American Diabetes Association // Diabetes Care. 2019. 42. Supplement 1. P. S13  S28. DOI: 10.2337/dc19-S002.

4.Chiang Jane L. Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association / Jane L. Chiang, M. Sue Kirkman, Lori M.B. Laffel, Anne L. Peters // Diabetes Care. 2014. 37(7). P. 20342054. DOI: 10.2337/dc141140.

5. ..       . . 9 / .. , .. , .. . ., 2019.

6. ..        / .. , .. , ..   . ., 2013.

7.Sacks B. Laboratory Medicine Practice Guidelines. Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. 2011.

8. ..   : 2. . 1. .: -, 2012.

9.,        :   15 /    . ., 1999.

10. ..      :    / ..   . 3- . .: -, 2017.

11.Simmons Kimber M. Islet Antibody Testing: Current Utility, Future Prospects in Predicting and Diagnosing Type 1 Diabetes / Kimber M. Simmons, Andrea K. Steck. 2017.

12.Diabetes Diagnostics. University of Exeter. 2016 (  iOS).

13. ..      1 . 2019.

14.Borai Anwar. The Biochemical Assessment of Insulin Resistance / Anwar Borai, Callum Livingstone, Gordon A.A. Ferns // Annals of Clinical Biochemistry. 2007. 44(4). P. 324342. DOI: 10.1258/000456307780945778/

15.         1      /    . 2013.

16.  1   :   /   . 2021.

17. ..    HNF1A     MODY 3:    / .. , .. , ..  //   . 2019. 47 (2). .180185. DOI: 10.18786/20720505201947021.

18.Unnikrishnan Ranjit. Challenges in Diagnosis and Management of Diabetes in the Young / Ranjit Unnikrishnan, Viral N. Shah, Viswanathan Mohan // Clinical Diabetes and Endocrinology. 2016. 2 (18). DOI: 10.1186/s4084201600366.

19.Pozzilli Paolo. Latent Autoimmune Diabetes in Adults: Current Status and New Horizons / Paolo Pozzilli, Silvia Pieralice // Endocrinology and Metabolism. 2018. 33(2). P. 147159. DOI: 10.3803/EnM.2018.33.2.147.

20. ..   1    / .. , ..  // URL: www.ivrach.ru (27.05.2005)/

21.Juszczak Agata. When to Consider a Diagnosis of MODY at the Presentation of Diabetes: Aetiology Matters for Correct Management / Agata Juszczak, Rebecca Pryse, Katharine R. Owen // Br J Gen Pract. 2016. 66(647). P. e457  e459. DOI: 10.3399/bjgp16X685537.




  2 












    2   ,    ,       -                -  [1, 6].


  

1.      ( ? 25/


)    :

     (  );

      (? 4);

   (? 140/90 . .    );

  ( ? 0,9 /,  ? 2,8 /);

      ()4

  - ;

   ;

  ,    (,    .).

2.      ().

3.     (),     ()  .

4.    45 .

5.            :

 2       ;

       ;

  ,    ( ,  , ,   .);

       .

      [2]:

1)       8     14  .  7,0     .                  ,             ,     30      [5];

2)   ();

3)  (HbA1C)  2011    .  HbA1C 6,5%     .        :   6,0  6,4%           ( ),      HbA1C  5,7  6,4%      [2, 3, 6].




  


       , ,   ,      [1, 4]:

  ? 45 

 2426-  

      ( ? 25/


)    :

?     (    2)

?    

?          

?       ( 3600)  

?   (? 140/90 . .    )

?   ? 0,9/ /   ? 2,82/

?   

?  - 


 [2]

    ,           ,    (,  , , -  ).

      :

   

     

   

   

 -


  

            150   ,         ,       3050 .

 :     814 ,   .


    :

 2     (    )

 3      

 75    82,5  

 250300  


  

1.    .

2.   5    75    82,5  ,   250300  (    1,75   ( 1,925  )    ,    75 (82,5).

3.        5 .

4.    ,  .

5. 2       .         1   2   .



!       ,        ,     04,           [2].



 

     ,        :    (),     ().

,    [2]:

1)   : ?6,1 / < 7/

/

2) 2    : ?7,8 / < 11, 1 /

      .

              (, ) 1   1 ,     1   3 .



 10







 


  2           ,      1 ,           [1, 4]:

 , 

 

   

   

  

   

 

 

   

  

       2       :     , , , .

             , ,  ,   ,  .       .      ,  ,      .




 





 


       .

     (HbA1C)       .

   .

         [2, 3, 6].

,     [2, 3, 6]:

1)   : ?7,0 /

2) 2        : ?11,1 /

3)HbA1C: ?6,5%

      !

             .

 HbA1C  6,0  ,  HbA1C   6,06,4%        .




 


     .         1  2 .

            .

  1   :

  

    

  ,   

  2   :

   40 

  

    : ,     ,  

  

 ,      2  .    2      40 ,      2        .

        [1, 4]:

1)  -  

2)    1 :  ICAs, GAD, IAAs

3)   ()  ,   ,    

         ,           [1].




 


1.  2 :     /  . .. , .. , .. . ., 2016.

2.      :   /  . .. , .. , ..  //  . 2019. . 22.

3.Standards of Medical Care in Diabetes  2021 / American Diabetes Association // Diabetes Care. 2021. 44. Supplement 1.

4..   /  . .. , .. . 2- . ., 2018.

5.Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of WHO/IDF Consultation. 2006.

6.Global Guideline for Type 2 Diabetes / International Diabetes Federation. 2012.




  





  











 (  )         .




 


 ,  ,     ,   ,   ,       (, ,   ).           ,   ,    ,   , ,  ,  .             .


 ,    

     (         ,        ).

  ,     (  (  ),  (   ,           ),   (  ),  ()).

       .

    .

   (        ( ,    .).




 








           ,    (2001 ):

0- ()     (           );

1-    ,       ;

2-         .

          .      :

1) () :       ,              ;

2)   ,   ,       .

    ,  ,  , ,  ,        .




 





     ,   ,           .      ,     ,     .

          EU-TIRADS.  .   .




 



    ()

       18,    25,         .

          .


 

            /    .           (   ).

 ,              .     ,    .




 


               .

         :  4,    ( ).

         :  3, 4,    .  .   .

 ,  :

   (        )

   (     (      ),     )




  










 


1.Walsh J.P. Managing Thyroid Disease in General Practice // Medical Journal of Australia. 2016

2.Ross Douglas S. Clinical Presentation and Evaluation of Goiter in Adults / Douglas S. Ross, David S. Cooper, Jean E. Mulder // UpToDate. 2021.

3. :  /  . . , . , . ; . .  . .. , .. . 2- ., . . .: -, 2009.  2. . 102162.

4. ..   .      :  //  . 2014.

5. ..       :     2019 ?   / .. , .. , ..  //    . 2019.

6.Zimmermann M.B. Iodine-deficiency Disorders / M.B. Zimmermann, P.L. Jooste, C.S. Pandav // Lancet. 2008.

7.WHO, UNICEF and ICCIDD. Assessment of Iodine Deficiency Disorders and Monitoring Their Elimination. Geneva: WHO, WHO/Euro/NUT, 2001.

8. .. . .:   , 2012.
















   ,               [1].




 


  :

 

 

 :

  (  ,       )

  ( , , ,    )

    :

 

 

 

     .1.






 1.    






 


          .

   :

  

 

    

  

  

  ,  ,  

 

  

 

  

 

   , 

     .     .2.






 2.  






 


          :

    

  

 -  

  




 


 :

    (> 4/)

  4    

 :

    (> 4/)

    4

         4      ,  4  23 ,     - [2].

 ,       (),      (-)   (-).

                    [2].

       4      /       [2].




 


                 .

             .




 













1.:   /  . .. , .. . 2- . .: -, 2020.

2.:  . 2021.




 











  ( ,   ,  ,  )      , ,    ,       .     (     ),         , ,     .       (  ,  1,6%         5,613,6    ).

   ()     ,       .        ,   ,  (  )   .  :  , ,   , -,       . ,       ,      HLA-BW35  HLA-B67    ,      -  ( 87%    ).




 


       .         :

 ;

      ;

  ;

 .

    :

       ,    ,   :

?                ;

?    ,   ,    ;

      3839C;

 , , ;

 ;

      ( 4060 /,     100 /)        .

     4  ():

1. (410 )

2. (13 )

3. (26 )

4.,       ( 15% ),   .











  :   ,   , , .

  :                .

  :           ,          ,   ,          .         .




 



  

: ,  23    ,  1   10 .

              (>50/)           ( ).        .        .

   ,     ,    -   5/.


  

    (, )      3  4 (      ) , ,   <0,1/.          ,    .            3  4    .

         ,      (-      ).      .           .       26 ,                .




 


  (       :  23    ,  1  3    ).

                  .   ,        :            .




  





  


           .               ,          .

          ( 13%).




 : .

 :    (    24    ).




    ()


  ,             .

      ,    ,         (), ,     .                 /    ,  ,   ,             , ,     .




    .  .




 


            .     2030    ( 10  23   ),    2472       .                .




   (  ).




 


         ,       :

      ,        (),      ()    .           .        .

      ,    .       ,             .         3.

           ,                    .       ,       .

       ,       .          .      , .  ,    .       ,        .

    .            .      , ,    .     ,      .     .

     ,     ,  ,     ,    .      ,          ,   .    C  ,  , 3  4  .       .




 


1. .. :   (   ) / .. , .. , .. , ..  // Consilium Medicum. 2019. 21 (12). .1022. DOI: 10.26442/20751753.2019.12.190683.

2. ..     (  ):   / .. , .. , ..   . //  . 2021. 67 (2). . 5783. URL: https://doi.org/10.14341/probl12747 (https://doi.org/10.14341/probl12747).

3.Fatourechi V. Clinical Features and Outcome of Subacute Thyroiditis in an Incidence Cohort: Olmsted County, Minnesota, Study / V. Fatourechi, J.P. Aniszewski, G.Z. Fatourechi et al. // J Clin Endocrinol Metab. 2003. 88 (5). P. 21002105. DOI: 10.1210/jc.2002021799. PMID: 12727961.

4.Nishihara E. Clinical Characteristics of 852 Patients with Subacute Thyroiditis before Treatment / E. Nishihara, H. Ohye, N. Amino et al. // Intern Med. 2008. 47 (8). P. 725729. DOI: 10.2169/internalmedicine.47.0740. PMID: 18421188.

5.Ohsako N. Clinical Characteristics of Subacute Thyroiditis Classified According to Human Leukocyte Antigen Typing / N. Ohsako, H. Tamai, T. Sudo et al. // The Journal of Clinical Endocrinology & Metabolism. 1995. 80 (12) P. 36533656. DOI: 10.1210/jcem.80.12.8530615.

6. ..   / .. , .. , ..   . //  . 2006. 52 (2). . 3543. URL: https://doi.org/10.14341/probl20065223543 (https://doi.org/10.14341/probl200652235-43).




  (  ,  )











  ,        ,               [1].




 


   - :

? 

?       =>      

?  

?  => 

  :

?      

?  , 

?  ,    ,  

    :

?  : , , , 

?      (          )

 :

?  

?   

?    

    

   - :

? 

?     ( )

  

    [2]

   ( )     .        :

?             (  ,   )

?             (    ,   )

?      

?                  ( )

?             (    3   1 )

?            








       :









 





   


              ,    .

          ,    4.

?    T4         :     T4        .

       T4  T3 ,     .

?       T4      T4   ,      T3    .




 


         .

           ,     .

               ,        [3].          ,      ,    [4].            ,      ,      . [3]




 





 


        .

?          18,   25.   ,  .

?       ,   ,  .

   /     .

       [4].







            .

?         (99mTc), 123I,  131I. 99mTc     (6 ),     .         3,2 ( :             ) [5, 6].

?           ,     (  ),       ,     [4].

           [2].

        ,                .

           ,         .

                   ,     ( ,   2 ).

   ,          ,        ,        [4].




 


 ,    :

?  () 

?  

?  

?  

?  

 ,     (, , ,  ,   2 ),           .       ( )   .

 ,     (-        )          4   3.

   (    ) [4]                [2].

    (    )     (  5060 );      ,     (-, -, -).

    [2]            ,          .                4   (  4   ,          ).




 





*              ,     99mTc, 123I  131I.






 


1. ..      //  . 2014. 4.

2. ..  / .. , .. , .. . ., 2007.

3.Kahaly G. J. European Thyroid Association Guideline for the Management of Graves Hyperthyroidism / G. J. Kahaly, L. Bartalena, L. Heged?s et al. // Eur Thyroid J. 2018. 7 (4). P. 167186.

4. ..          / .. , .. , ..   . //  . 2014. 6.

5.Lee J.C. Thyroid Scans / J.C. Lee, F.A. Khafagi // Aust Fam Physician. 2012. 41 (8). P. 584586. PMID: 23145398.

6.Radiation Dose in X-Ray and CT Exams / Radiological Society of North America. 2021.




   











   ()     -       (, )   .    .          ,          ,        .                      () .                 ,         .       ,    ,    .   ,    ,             (    ).

        ,    ,                 .




 


               45 .

:

     / 

     (      )

     ()

:

   -   ,    (   ,  ,    , ),    (   )

  ,  , , 

    

:

         




 







-, -,  ,  (                ).

:

       (   )          (       - ).

                      NT-proBNP (N-     ),       556,4/.

   NT-proBNP (>125/)        ,    .




 





  


  ,  .

    :








    :



 11






   :

                     .      ,    ,    

      ()  ,  ,   




 


  / ,          ,          .

    (),    99mTc,       (  ).

                 .




 




 12













 










 


1.          (  ,    ), /  /   . ., 2014. 25.

2. .. :   / .. , . . . 2- ., . . .: -, 2016. 1112.

3. ..    .   .    . .: -, 2019. 208.

4. ..              / .. , .. , ..   . //    . 2006. . 2. 1. .5160.

5. ..             2016  //    . 2017. . 13. 3. .4556.

6. .. -              / .. , .. , .. , ..  //   . 2019. 24 (11). .2834.




 












    :

    ()    ;

              ().

    :

  ;

 ;

    ()     ;

  ;

 .




  


       ,    ,      .

   2001   3   :

  0   

  1   ,       

  2       




,    


      

     2  

   20   70 

  

   

    

  

   

  , ,   




 


               .

?          ,       .

           4   3,         4.

            ,         .     > 100/,      .   ,      ,  < 100/,      .




-


           .

   :

       ,          ;

  ,              .




     (     )

    

     (      ,  )

      

   

   ,    ,   

      (     )

   

   , , , , ,  ,  ,   .  ,         .         .   -       TI-RADS,   2009  E.Horvath      2011  J.Y. Kwak  .






 3. Thyroid Imaging Reporting and Data System (TI-RADS)



    (AACE),    (ACE)     (AME)      ,   -.

  1.    

?        ,     -    

?       ()

?    <1%

  2.    

?   (    )    -      

?  ,  ,     ,          

?     5  15%

  3.    . ,       -:

?   (    )

?    

? 

?     

?     

?     50  90%         

              ,  American Thyroid Association (ATA)  2015 :

    (> 7090%)

?          -       :  , ,   ,  ,  ,      

?     ? 1 

    (1020%)

?       ,   ,    ,  

?     ? 1 

    (510%)

?      -        ,   ,    ,  

?     ? 1,5 

     (< 3%)

?   -    ,    ,     

?      ? 2.         

  (< 1%)

?    (  )

?   




  


          .    -     (,  , ,   ).       TI-RADS   ATA   .

       2020 :

       1  

   < 1,           :

?      > 100/

?     

?      

?   

?   

?   ,    - 

?   20 

?          

  , :

    1,        ,      -  ;

                  ;

            ,                  ;

                           .




  .


   .

   ,     (https://www.litres.ru/book/aleksandr-kozhevnikov-31326436/diagnostika-v-endokrinologii-66257378/)  .

      Visa, MasterCard, Maestro,    ,   ,     ,  PayPal, WebMoney, ., QIWI ,       .


